SCHOTT and Serum Institute announce JV for pharma packaging
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Filing for WHO Emergency Use Authorisation this month
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Subscribe To Our Newsletter & Stay Updated